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Background/Aims: This retrospective study evaluated the transplantation outcomes of patients with adult lymphoid 
malignancies who received chemotherapy-based conditioning with busulfan and fludarabine (BuFlu) and busulfan and 
cyclophosphamide (BuCy2).
Methods: Thirty-eight patients (34 with acute lymphoblastic leukemia and 4 with lymphoblastic lymphoma) were included 
in the current study. The conditioning regimen was BuCy2 for 14 patients and BuFlu for the remaining 24 patients. Eight 
and 13 patients were high risk disease in the BuCy2 and BuFlu groups, respectively.
Results: The cumulative incidence of grade II-IV acute graft-versus-host disease (GVHD) was 56.5% and 55.2% and 
that of extensive chronic GVHD 17.0% and 55.6% (p = 0.018) for the BuFlu and BuCy2 groups, respectively. The 3-year 
relapse rate was 27.8% and 31.4% and 3-year overall survival 34.3% and 46.8% for the BuFlu and BuCy2 groups, 
respectively. Treatment-related mortality (TRM) was significantly lower in the BuFlu group (16.9%) than in the BuCy2 group 
(57.1%, p = 0.010). In multivariate analyses, the BuFlu regimen was identified as an independent favorable risk factor for 
TRM (hazard ratio [HR], 0.036; p = 0.017) and extensive chronic GVHD (HR, 0.168; p = 0.034). 
Conclusions: Our BuFlu regimen would appear to be an acceptable conditioning option for lymphoid malignancies, 
including high-risk diseases. It was safely administered with a lower TRM rate than BuCy2 conditioning.
Keywords: Precursor cell lymphoblastic leukemia-lymphoma; Busulfan; Drug therapy; Fludarabine
INTRODUCTION
Chemotherapy-based conditioning is widely used 
for myeloid leukemia due to its ease of administration, 
reduced incidence of long-term sequelae compared to 
total body irradiation (TBI) conditioning, and equivalent 
transplantation outcomes with regard to treatment-related 
mortality (TRM), relapse, and leukemia-free survival 
(LFS) [1-5]. However, while this holds true for myeloid 
leukemias, there is some controversy in the case of acute 
lymphoblastic leukemia (ALL) due to a less potent anti-
tumor effect at sanctuary sites [6,7].
Busulfan and cyclophosphamide (BuCy2) regimens have 
been standard treatments for achieving myeloablative 
conditioning since the publication of studies by the 
European Group for Blood and Marrow Transplantation 
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(EBMT) and Center for International Blood and Marrow 
Transplant Research (IBMTR) that demonstrated the 
equivalence of BuCy2 and CyTBI regimens [1,2]. However, 
the major concern with BuCy2 conditioning is the high 
TRM caused by cyclophosphamide metabolites [8,9]. 
Meanwhile, fludarabine has considerable and synergistic 
efficacy in both immunosuppression and tumor-cell 
killing when administered with an alkylating agent, and 
is widely used as an alternative to cyclophosphamide in 
reduced-intensity and myeloablative conditioning [10-13]. 
This retrospective study evaluated the transplantation 
outcomes of patients with adult lymphoid malignancies 
who received chemotherapy-based conditioning with 
busulfan and fludarabine (BuFlu), adopted to avoid the 
sequelae of TBI conditioning and the toxicity of standard 
BuCy2 conditioning.
METHODS
Patients and transplantation procedures
We retrospectively reviewed the data for 38 patients 
with lymphoid malignancies who underwent allogeneic 
stem cell transplantation (SCT) at Kyungpook National 
University Hospital, Daegu, Korea between December 
1998 and November 2009. The median follow-up after 
transplantation was 255 days (range, 9 to 2,804) and all 
of the patients received chemotherapy-based conditioning 
with BuCy2 or BuFlu. BuCy2 conditioning was used for 
patients who underwent transplantation before 2005 and 
BuFlu was used for those who received transplants after 
2005. This study was approved by the local institutional 
review boards. 
Until January 2008, human leukocyte antigen (HLA) 
typing was performed through serologic testing for class I 
alleles (A, B, and C) and DNA-based typing for HLA class 
II molecules (DRB1). However, since then, HLA-typing 
has been achieved through high-resolution genotyping of 
HLA class I and II alleles. Prophylaxis against acute graft-
versus-host disease (GVHD) consisted of methotrexate 
(MTX) plus cyclosporine for sibling donors and tacrolimus 
for unrelated donors. Most patients were scheduled to 
receive MTX (15 mg/m
2 on day 1 and 10 mg/m
2 on days 3, 6, 
and 11). The last dose of MTX was omitted when mucositis 
higher than grade 4 or renal impairment was observed. 
Cyclosporine was initially administered at a dose of 5.0 
mg/kg/day via continuous infusion on the day before the 
transplantation. The dose was reduced to 2.5 mg/kg/day 
via continuous infusion on day +7, and then changed to an 
oral dose of 3 mg/kg twice daily when tolerated. Starting 
on day 60, the oral cyclosporine dose was reduced by 5% 
per week, and then maintained at 1.5 mg/kg/day until 
day 270 for patients without symptomatic chronic GVHD. 
Tacrolimus was administered intravenously at a dose 
of 0.03 mg/kg/day on the day before transplantation. 
Through therapeutic drug monitoring, the blood level 
of tacrolimus was maintained within the range of 15-20 
ng/mL for the first months and 10-15 ng/mL thereafter. 
Patients subsequently received a daily oral dose three 
to four times higher than the last intravenous dose. 
For the purpose of in vivo T cell depletion (TCD), anti-
thymocyte globulin (ATG) was used in patients with HLA-
mismatched or unrelated donors. 
The prophylactic antibiotics consisted of ciprofloxacin 
(250 mg, twice daily, orally), metronidazole (500 mg, 
three times daily, orally), and fluconazole (100 mg, 
once daily, orally) from the initiation of conditioning. 
Acyclovir (600 mg, twice daily, orally) was started from 
day-1 and cotrimoxazole was started after engraftment. 
Ursodeoxycholic acid was used for veno-occlusive disease 
(VOD) prophylaxis from the initiation of conditioning. 
Conditioning regimens 
For the myeloablative BuCy2 regimen, busulfan 
(Busulfex, Orphan Medical Inc., Minnetonka, MN, 
USA) was infused intravenously at a dose of 3.2 mg/kg/
day for 4 days (total dose 12.8 mg/kg, days -7 to -4), and 
cyclophosphamide was infused intravenously at a dose 
of 60 mg/kg/day for 2 days (total dose, 120 mg/kg; days, 
-3 to -2). For the myeloablative BuFlu regimen, busulfan 
was infused intravenously at a dose of 3.2 mg/kg/day 
for 4 days (total dose, 12.8 mg/kg; days, -6 to -3), and 
fludarabine was administered intravenously at a dose of 
30 mg/m
2 for 6 days (total dose, 180 mg/m
2/day; days, -7 
to -2). For the reduced-intensity BuFlu regimen, busulfan 
was infused intravenously at a dose of 3.2 mg/kg/day for 2 
days (total dose, 6.4 mg/kg; days, -5 to -4); the fludarabine 
schedule was the same as for the standard BuFlu regimen. 
GVHD grading and treatment
Diagnosis and grading of acute GVHD were performed 
according to the consensus conference guidelines for acute 74    The Korean Journal of Internal Medicine Vol. 27, No. 1, March 2012
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GVHD [14]. The frontline treatment for acute GVHD was 
the prednisone (1-2 mg/kg/day). In patients with acute 
GVHD who did not respond to steroids and cyclosporine, 
cyclosporine was replaced with tacrolimus. 
Chronic GVHD was diagnosed and graded based 
on published criteria [15]. The initial treatment for 
chronic GVHD was prednisone (1-2 mg/kg/day) and 
the reintroduction of cyclosporine or tacrolimus in the 
therapeutic range [16]. If further immunosuppressive 
agents were needed to control chronic GVHD, the salvage 
regimen included the use of mycofenolate mofetile (MMF), 
ATG, weekly MTX, or combination therapy [17,18]. MMF 
was added at a dose of 1.5 or 2 g/day and the steroids doses 
were tapered in refractory cases (by 0.2 mg/kg/wk). The 
dose of MMF was escalated to 2 g/day in patients with 
progressive GVHD.
Definitions
The day of stem cell infusion was defined as day 0. 
Myeloid engraftment was defined as the first day of a 
period of at least three consecutive days with an absolute 
neutrophil count (ANC) of ≥ 0.5 × 10
9/L, while platelet 
engraftment was defined as the first day of at least three 
consecutive days on which a platelet count of ≥ 20 × 10
9/L 
was achieved without transfusion. High-risk patients were 
defined as patients older than 35 years or those with a high 
white blood cell count at presentation (≥ 100 × 10
9/L for 
B-lineage cells and ≥ 30 × 10
9/L for T-lineage cells), along 
with all patients with Philadelphia chromosome. TRM was 
defined as mortality related to stem cell transplantation 
procedures, e.g., VOD, GVHD, and infection. 
Statistical analysis
Continuous variables were compared using the two-
sample t test, while categorical data were analyzed using 
the chi-square test. Overall survival (OS) was defined 
as the time from transplantation until death from any 
cause, and was analyzed using a Kaplan-Meyer test. Both 
groups were compared using a log-rank test or Breslow 
test. The cumulative incidence of chronic GVHD was 
calculated by Gray’s method (with death or relapse without 
chronic GVHD considered as competing risks) using 
the R software package cmprsk. A time-dependent Cox 
regression model was used to identify clinical predictors 
of the development of chronic GVHD and TRM. Factors 
with p values of 0.1 or less in the univariate analysis were 
included in the multivariate analysis and the variables 
were analyzed using backward inclusion methods. For the 
statistical analyses, SPSS version 13 (SPSS Inc., Chicago, 
IL, USA) and R statistical software version 2.8.0 (R 
Foundation for Statistical Computing, Vienna, Austria; 
http://www.r-project.org) were used. A p value of < 0.05 
was considered significant.
RESULTS
Patient characteristics
Thirty-four patients were diagnosed with ALL and four 
with lymphoblastic lymphoma. The conditioning regimen 
was BuCy2 for 14 patients and BuFlu for 24 patients. Six 
patients underwent reduced-intensity BuFlu conditioning 
(RIC). Median age in the BuCy2 and BuFlu groups was 
31 years (range, 18 to 48) and 33 years (range, 22 to 53), 
respectively. There were 13 (54.2%) and 8 (57.1%) high-
risk patients in the BuCy2 and BuFlu groups, respectively, 
including 1 (7.1%) and 7 (29.2%) Ph-chromosome-positive 
cases, respectively (p = 0.859). Initial extramedullary 
involvement was present in four (28.6%) and two (2.8%) 
patients in the BuCy2 and BuFlu groups, respectively 
(p = 0.099). The pretransplantation procedures were 
comparable regarding HLA-mismatched donors (7.1% vs. 
16.7%, p = 0.370), unrelated donors (28.6% vs. 58.3%, p = 
0.076), and peripheral blood stem cells (85.7% vs. 91.7%, p 
= 0.564). The other patient characteristics are summarized 
in Table 1.
Survival 
The survival rate for all patients at 3 years was 41.8% 
(95% confidence interval [CI], 27.5 to 63.4) with a median 
follow-up duration of 982 days (95% CI, 634 to 1,329). 
The 3-year OS rate was 53.8% (95% CI, 33.7 to 86.0) for 
standard-risk patients and 30.6% (95% CI, 14.3 to 65.1) for 
the high-risk patients (p = 0.213) (Fig. 1), while the 3-year 
relapse rate was 14.7% for the standard-risk patients and 
43.3% for the high-risk patients (p = 0.109). Patients with 
chronic GVHD had a better 3-year OS rate (64.0%) than 
those without chronic GVHD (24.0%, p = 0.002) (Fig. 
1). The 3-year OS for the BuCy2 and BuFlu groups was 
34.3% and 46.8%, respectively (p = 0.279) (Fig. 2), while 
the 3-year event-free survival (EFS) rate was 25.7% and 
47.1%, respectively (p = 0.215) (Fig. 2). Relapse occurred Shin HC, et al. BuFlu conditioning for malignant lymphoid disease    75
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Table 1. Patient characteristics
Characteristics BuCy2 BuFlu p value
No. of patients 14 24
Age, yr 31 (18-48)   33 (22-53) 0.366
Gender
   Male  9 (64.3) 14 (58.3) 0.717
   Female 5 (35.7) 10 (41.7)
Diagnosis
   ALL 12 (85.7) 22 (91.7) 0.564
   LL 2 (14.3) 2 (8.3)
Immunophenotype
   B-cell 5 (35.7) 15 (62.5) 0.111
   T-cell 9 (64.3)  9 (37.5)
Cytogenetic risk group
   Standard  10 (71.4) 12 (50.0) 0.412
   High 3 (21.4) 10 (41.7)
   NE 1 (7.1) 2 (8.3)
Ph chromosome 1 (7.1)   7 (29.2) 0.108
   Use of imatinib 0   6 (25.0)
Extramedullary
   CNS 4 (28.6) 2 (8.3) 0.099
Disease status
   CR1 6 (42.9) 18 (75.0) 0.163
   CR2 3 (21.4) 2 (8.3)
   Primary refractory 2 (14.3)   3 (12.5)
   Relapsed 3 (21.4) 1 (4.2)
Risk group 
   Standard 6 (42.9) 11 (45.8) 0.859
   High 8 (57.1) 13 (54.2)
HLA 
   Full match 13 (92.9) 20 (83.3) 0.370
   One mismatch 1 (7.1) 1 (4.2)
   Haploidentical 0   3 (12.5)
Donor 
   Sibling   10 (71.4)   10 (41.7) 0.076
   Unrelated 4 (28.6) 14 (58.3)
Stem cell source
   PB 12 (85.7)   22 (91.7) 0.564
   BM 2 (14.3) 2 (8.3)
Conditioning 
   MA  14 (100) 18 (75.0) 0.067
   RIC 0   6 (25.0)
GVHD prophylaxis 
   Cyclosporine 11 (78.6) 11 (45.8) 0.049
   Tacrolimus 3 (21.4) 13 (54.2)
In vivo TCD 4 (28.6)    9 (37.5) 0.576
MNCs (× 10
8/kg)      7.81 (1.34-17.96)          9.79 (0.36-18.43) 0.757
CD34+ cells (× 10
6/kg)     4.95 (1.85-15.14)        5.79 (1.53-19.20) 0.518
Values are presented as mean (range) or number (%).
Bu, busulfan; Cy, cyclophosphamide; Flu, fludarabine; ALL, acute lymphoblastic leukemia; LL, lymphoblastic lymphoma; NE, not evalu-
able; CNS, central nervous system; CR, complete remission; HLA, human leukocyte antigen; PB, peripheral blood; BM, bone marrow; 
MA, myeloablative; RIC, reduced-intensity conditioning; GVHD, graft-versus-host disease; TCD, T-cell depletion; MNC, mononuclear 
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in three patients (21.4%) in the BuCy2 group and six 
patients (25.0%) in the BuFlu group (p = 0.803) (Table 2). 
The cumulative incidence of 3-year relapse for the BuCy2 
and BuFlu groups was 27.8% and 31.4%, respectively (p = 
0.476) (Fig. 3). 
Graft-versus-host disease 
The incidence of acute GVHD did not differ between 
the two groups. Grade II-IV acute GVHD developed in 7 
(50.0%) of the 14 patients in the BuCy2 group at a median 
of 15 days (range, 9 to 22) and in 7 (29.2%) of the 24 
patients in the BuFlu group at a median of 24 days (range, 
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Figure 1. Survival rates according to risk group and presence of graft-versus-host disease (GVHD). (A) Overall survival according to 
risk group. The 3-year overall survival (OS) rate was 53.8% (95% confidence interval, 33.7 to 86.0) for standard-risk patients and 30.6% 
(95% confidence interval, 14.3 to 65.1) for high-risk patients. (B) Overall survival according to presence of chronic GVHD. Patients with 
chronic GVHD showed a better 3-year OS rate (64.0%) than those without chronic GVHD (24.0%). 
Figure 2. Survival analyses according to conditioning regimen. (A) Overall survival. The 3-year overall survival rates for the busulfan-
cyclophosphamide (BuCy2) and busulfan-fludarabine (BuFlu) groups were 34.3% and 46.8%, respectively. (B) Event-free survival. The 
3-year event-free survival rates for the BuCy2 and BuFlu groups were 25.7% and 47.1%, respectively. 
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12 to 64) (p = 0.199) (Table 2). The cumulative incidence 
of grade II-IV acute GVHD 100 days after transplantation 
was 56.5% in the BuCy2 group and 55.2% in the BuFlu 
group (p = 0.130) (Fig. 4). Among patients who survived 
longer than 3 months after transplantation, limited and 
extensive chronic GVHD developed in two (22.2%) and 
five (55.6%) patients, respectively, in the BuCy2 group, 
and in six (35.3%) and two (11.8%) patients, respectively, 
in the BuFlu group (p = 0.054) (Table 2). The cumulative 
incidence of extensive chronic GVHD after transplantation 
in the BuFlu group (17.0%) was lower than that in the 
BuCy2 group (55.6%; p = 0.018) (Fig. 4). 
In univariate analyses, complete remission (CR) (hazard 
ratio [HR], 3.999; p = 0.077), the BuFlu regimen (HR, 
0.168; p = 0.034), and hyperacute GVHD (HR, 5.847; 
p = 0.054) were identified as factors affecting TRM. 
Meanwhile, multivariate analysis identified the BuFlu 
regimen (HR, 0.144; 95% CI, 0.026 to 0.803; p = 0.027) as 
an independent favorable risk factor for the development 
of extensive chronic GVHD (Table 3). 
Treatment-related mortality
TRM affected eight patients (57.1%) in the BuCy2 
group and three patients (12.5%) in the BuFlu group (p 
= 0.008) (Table 2). The cumulative incidence of TRM 
was significantly lower in the BuFlu group (16.9%) than 
in the BuCy2 group (57.1%, p = 0.010) (Fig. 3). Causes of 
TRM in the BuCy2 group included infection (two patients, 
14.3%), chronic GVHD (two, 14.3%), VOD (two, 14.3%), 
and brain hemorrhage (two, 14.3%); in the BuFlu group, 
they included infection (two patients, 8.3%) and VOD (one, 
4.2%).
In univariate analyses, the BuFlu regimen (HR, 0.201; 
p = 0.018), VOD (HR, 3.931; p = 0.031), and hyperacute 
GVHD (HR, 3.232; p = 0.062) were identified as 
significant factors affecting TRM. Multivariate analysis 
identified the BuFlu regimen (HR, 0.199; 95% CI, 0.052 to 
0.752; p = 0.017) as an independent favorable risk factor 
Table 2. Transplantation outcomes
Variables BuCy2 BuFlu p value
No. of patients 14 24
Engraftment
ANC ≥ 0.5 × 10
9/L, day 14 (10-27) 12 (9-18) 0.073
Platelet ≥ 20 × 10
9/L, day 13 (10-33) 12 (7-26) 0.125
Acute GVHD, grade II-IV 7 (50.0)   7 (29.2) 0.199
Chronic GVHD
a, type
 De novo  2 (22.2) 0 0.088
 Quiescent  3 (33.3)  7 (41.2)
 Progressive  2 (22.2) 1 (5.9)
Chronic GVHD
a, severity
 Limited 2 (22.2)   6 (35.3) 0.054
 Extensive  5 (55.6)  2 (11.8)
Veno-occlusive disease 
 Moderate  1 (7.1)   4 (16.7) 0.058
 Severe  2 (14.3) 0
CMV reactivation 11 (78.6) 12 (50.0) 0.082
Treatment-related mortality  8 (57.1)   3 (12.5) 0.008
Relapse 3 (21.4)   6 (25.0) 0.803
 Central nervous system relapse 1 1
Death  10 (71.4) 10 (41.7) 0.076
Values are presented as mean (range) or number (%).
Bu, busulfan; Cy, cyclophosphamide; Flu, fludarabine; ANC, absolute neutrophil count; GVHD, graft-versus-host disease; CMV, cyto-
megalovirus.
a26 patients (9 + 17) who survived longer than 3 months after transplantation were analyzed.78    The Korean Journal of Internal Medicine Vol. 27, No. 1, March 2012
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for TRM, and VOD (HR, 3.951; 95% CI, 1.148 to 13.598; p 
= 0.029) as an unfavorable risk factor for TRM (Table 4).
Extramedullary disease 
Among the six patients who presented with extram-
edullary involvement at the time of diagnosis, the five 
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Figure 3. Relapse and treatment-related mortality (TRM) according to conditioning regimen. (A) Cumulative incidence of relapse. The 
cumulative incidence of 3-year relapse for the busulfan-cyclophosphamide (BuCy2) and busulfan-fludarabine (BuFlu) groups was 27.8% 
and 31.4%, respectively. (B) Treatment-related mortality. The cumulative incidence of TRM was significantly lower for the BuFlu group 
(16.9%) than for the BuCy2 group.
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Figure 4. Graft-versus-host disease (GVHD) according to conditioning regimen. (A) Cumulative incidence of grade II-IV acute GVHD. 
The cumulative incidence of grade II-IV acute GVHD at 100 days after transplantation was 56.5% for the busulfan-cyclophosphamide 
(BuCy2) group and 55.2% for the busulfan-fludarabine (BuFlu) group. (B) Cumulative incidence of extensive chronic GVHD. Among pa-
tients who survived longer than 3 months after transplantation, the cumulative incidence of extensive chronic GVHD after transplanta-
tion was lower in the BuFlu group (17.0%) than in the BuCy2 group (55.6%). 
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with positive cerebrospinal fluid cytology were treated 
with intrathecal chemotherapy, while the remaining 
patient, who had a central nervous system (CNS) mass, 
was treated with brain radiotherapy and intrathecal 
chemotherapy (Table 5). All six patients were treated 
successfully with no CNS system relapse, although four of 
them experienced bone marrow relapse and the patient 
with the CNS mass developed a pelvic mass, which was 
successfully treated with radiotherapy and dasatinib 
treatment. Extramedullary relapse was observed in two 
of the nine patients who relapsed. Two of the thirty-
two patients without extramedullary involvement at 
presentation experienced recurrence in the CNS as well as 
the BM, even though they had received prophylactic CNS 
treatment. However, both of these patients presented with 
complex cytogenetic abnormalities at the time of diagnosis 
and did not show any evidence of chronic GVHD after 
transplantation. 
DISCUSSION
Many studies have already investigated substituting 
busulfan for TBI to reduce the long-term side effects 
of TBI, and randomized studies comparing TBI-based 
and non-TBI-based regimens have shown comparable 
results for myeloid leukemias. However, experience with 
chemotherapy-based regimens is limited, especially 
Table 3. Factors affecting the development of extensive chronic GVHD
Univariate analysis Multivariate analysis
Variables HR 95% CI p value HR 95% CI p value
Sex 0.469  0.089-2.457 0.370
Age > 35 yr 1.960  0.437-8.791 0.380
Transplantation year, 
> 2006 vs. ≤ 2005 0.269  0.051-1.420 0.122
Diagnosis, LL vs. ALL 1.082    0.130-9.008 0.942
IP type, T-cell vs. B-cell 0.849  0.189-3.817 0.831
CG risk, high 0.829   0.149-4.595 0.830
LDH, high 1.407     0.168-11.761 0.752
EM disease 2.870    0.540-15.264 0.216
Status, non-CR 3.999    0.861-18.560 0.077 5.119   0.928-28.230 0.061
High risk 1.598 0.355-7.201 0.542
RIC vs. MA 0.036  0.000-159.988 0.439
BuFlu vs. BuCy2 0.168  0.032-0.874 0.034 0.144 0.026-0.803 0.027
Tacrolimus vs. CSA 0.256  0.031-2.134 0.208
Donor, unrelated vs. sibling 0.922  0.206-4.135 0.915
BM vs. PBSCs 1.007  0.118-8.626 0.995
TCD 0.208  0.025-1.733 0.146
HLA mismatch 0.043  0.000-8464 0.613
CD34 > 5 (× 10
6/kg) 1.270  0.282-5.720 0.756
VOD 0.040  0.000-1513 0.550
CMV 2.629 0.315-21.913 0.372
haGVHD 5.847 0.973-35.127 0.054 4.122    0.502-33.812 0.187
aGVHD ≥ 2 1.064  0.237-4.774 0.936
GVHD, graft-versus-host disease; HR, hazard ratio; CI, confidence interval; LL, lymphoblastic lymphoma; ALL, acute lymphoblastic 
lymphoma; IP type, immunophenotype; CG, cytogenetic; LDH, lactate dehydrogenase; EM, extramedullary; CR, complete remission; 
RIC, reduced-intensity conditioning; MA, myeloablative; BuFlu, busulfan-fludarabine; BuCy2, busulfan-cyclophosphamide; CSA, 
cyclosporine; BM, bone marrow; PBSC, peripheral blood stem cells; TCD, T-cell depletion; HLA, human leukocyte antigen; VOD, veno-
occlusive disease; CMV, cytomegalovirus; haGVHD, hyperacute GVHD; aGVHD, acute GVHD.80    The Korean Journal of Internal Medicine Vol. 27, No. 1, March 2012
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for adult patients with ALL. Moreover, there have been 
conflicting outcomes [1-5]. 
In the current study, when using non-TBI-based 
conditioning, the survival rate was comparable to that 
reported in previous studies, with an overall 3-year OS 
rate of 41.8% (53.8% for the standard-risk patients and 
30.6% for the high-risk patients) (Fig. 1). Meanwhile, 
patients with chronic GVHD showed a better survival 
rate than those without chronic GVHD, demonstrating 
the strong anti-leukemia effect of GVHD. These results 
are supported by the results of the subgroup analysis in 
the EBMT trial, which found no significant differences 
between patients treated with BuCy2 and those treated 
with CyTBI in terms of TRM, the incidence of relapse, or 
LFS [1]. LFS among allograft recipients with intermediate-
risk ALL was 43 ± 6% in the BuCy2 group and 33 ± 6% 
in the CyTBI group, a difference that was not statistically 
significant. However, there remains some controversy over 
the role of non-TBI conditioning in ALL patients. 
BuCy2 has been used in adult patients with ALL and 
has an LFS rate that is comparable to those of radiation-
containing regimens [19]. In contrast, in a study conducted 
by Granados et al. [20], TBI was associated with a lower 
relapse rate and better EFS than a busulfan-based 
Table 4. Factors affecting the development of TRM
Univariate Multivariate
HR 95% CI p value HR 95% CI p value
Sex 1.709  0.521-5.606 0.377
Age > 35 yr 1.340  0.407-4.409 0.630
Transplantation year, 
> 2006 vs. ≤ 2005 0.479   0.140-1.640 0.241
Diagnosis, LL vs. ALL 0.723  0.092-5.668 0.758
IP type, T-cell vs. B-cell 1.455 0.443-4.775 0.536
CG risk, high 0.713   0.184-2.762 0.624
LDH, high 0.742  0.154-3.586 0.711
EM disease 1.258   0.272-5.829 0.769
Status, non-CR 1.317 0.349-4.972 0.685
High risk 1.522 0.444-5.214 0.504
RIC vs. MA 0.036   0.000-23.294 0.314
BuFlu vs. BuCy2 0.201 0.053-0.759 0.018 0.199 0.052-0.752 0.017
Tacrolimus vs. CSA 0.552  0.146-2.083 0.380
Donor, unrelated vs. sibling 0.661 0.193-2.259 0.509
BM vs. PBSCs 0.040   0.000-76.339 0.403
TCD 0.330  0.071-1.535 0.158
HLA mismatch 0.663 0.084-5.197 0.659
CD34 > 5 (× 10
6/kg) 2.583 0.680-9.806 0.163
VOD 3.931    1.133-13.643 0.031 3.951    1.148-13.598 0.029
CMV 0.455 0.137-1.511 0.199
haGVHD 3.232  0.944-11.068 0.062 2.764   0.657-11.633 0.166
aGVHD ≥ 2 1.272  0.387-4.178 0.692
cGVHD 0.324   0.084-1.245 0.101
ecGVHD 0.719  0.155-3.338 0.673
TRM, treatment-related mortality; HR, hazard ratio; CI, confidence interval; LL, lymphoblastic lymphoma; ALL, acute lymphoblastic lym-
phoma; IP type, immunophenotype; CG, cytogenetic; LDH, lactate dehydrogenase; EM, extramedullary; CR, complete remission; RIC, 
reduced-intensity conditioning; MA, myeloablative; BuFlu, busulfan-fludarabine; BuCy2, busulfan-cyclophosphamide; CSA, cyclospo-
rine; BM, bone marrow; PBSC, peripheral blood stem cells; TCD, T-cell depletion; HLA, human leukocyte antigen; VOD, veno-occlusive 
disease; CMV, cytomegalovirus; haGVHD, hyperacute graft-versus-host disease; aGVHD, acute GVHD; cGVHD, chronic GVHD; ec-
GVHD; extensive chronic GVHD.Shin HC, et al. BuFlu conditioning for malignant lymphoid disease    81
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conditioning regimen. However, it is difficult to compare 
the results directly because Granados et al. [20] included 
some childhood ALL cases, which might have affected 
the outcomes, and used oral busulfan instead of IV 
busulfan. The inferior survival rate for BuCy2 patients, 
especially children, was likely due to the oral busulfan 
used in these trials. The intestinal absorption of oral 
busulfan is unpredictable, causing inter-patient variability 
in the plasma concentration. Moreover, the total plasma 
clearance rate is two to four times higher in children than 
in adults [21-25]. In contrast, intravenous preparations 
of busulfan produce a more predictable steady-state 
concentration, resulting in a lower incidence of hepatic 
VOD and better 100-day survival [26]. 
Experience with fludarabine-containing conditioning 
for adult ALL patients is very limited. In a study by Iravani 
et al. [13] using a myeloablative BuFlu conditioning 
regimen, the 1-year OS for ALL patients was 55.6%, with 
a 33.3% relapse rate at 1 year. In the current study, the 
outcomes for BuFlu conditioning were comparable to those 
for BuCy2 in terms of OS, EFS, and incidence of relapse 
(Figs. 2 and 3). The cumulative incidence of extensive 
chronic GVHD was significantly lower in the BuFlu group 
than in the BuCy2 group. Indeed, the BuFlu regimen was 
an independent favorable risk factor for the development 
of extensive chronic GVHD. In addition, while the higher 
relative incidence of TRM remains a major concern for 
patients receiving BuCy2 conditioning [12,13], this was 
not a significant issue for patients who received BuFlu 
conditioning (Table 4). However, interpretation of the 
current results requires caution because the disease 
status before transplantation was different in the two 
groups and, as BuFlu conditioning was performed more 
recently, improvements in supportive care may have 
contributed to the favorable outcome regarding TRM in 
the BuFlu group. CR1 was achieved in more patients in the 
BuFlu group (75.0%) than in the BuCy2 group (42.9%).     
Moreover, although only a small number of patients 
with the Philadelphia chromosome were included in the 
current study, tyrosine kinase inhibitors were used in 
more patients in the BuFlu group. In terms of conditioning 
intensity, RIC in the BuFlu group also confounded the 
difference in incidence of GVHD between the groups [27]. 
In addition, to achieve more meaningful results requires 
analysis of the data after distinguishing between sibling 
and unrelated donors and a larger sample size.
The major concern with chemotherapy-based 
conditioning in ALL is overcoming the blood-brain 
barrier. Bunin et al. [6] reported 5 cases of extramedullary 
relapse (23.8%) with BuCy2 and 2 cases of testicular 
relapse (9.1%) with TBI, but only 1 case of CNS relapse out 
of 52 patients who followed a BuCy2 regimen, this patient 
having previously received cranial irradiation to treat 
multiply relapsed CNS leukemia [6]. Meanwhile, in the 
present study, extramedullary relapse in the CNS was only 
observed in 2 of the 32 patients without extramedullary 
involvement at presentation, and both of these patients 
had complex cytogenetic abnormalities at presentation 
and exhibited no evidence of chronic GVHD after 
transplantation. Recent studies have indicated that the 
graft-versus-leukemia (GVL) effect may play a significant 
role in preventing CNS relapse in patients with lymphoid 
Table 5. Patients with extramedullary disease
Patients Initial EMD Cytogenetics IP Status Treatment GVHD Relapse Current status
M/18 CNS normal T Rel2 IT Extensive BM   Dead (D + 551)
F/28 CNS,
retinopathy
normal T Rel3 IT NE NE Dead (D + 9) 
F/28 CNS mass Ph+ Pre-B, T Ref RT + IT Limited BM, pelvic mass
a    Alive (D + 358)
M/30 CNS normal T Ref IT Extensive no       Alive (D + 2236)
F/38 CNS t(7p;22q) B Ref IT no BM   Dead (D + 113)
M/39 CNS t(7q;12q) Pre-B CR4 IT no BM   Dead (D + 62)
M/25 - -7,-19,+5 Pre-B, T CR2 IT
b no CNS mass     Dead (D + 1719)
M/46 - t(1;19),2q-,6q- Pre-B Ref IT
b no BM , CNS   Dead (D + 112)
EMD, extramedullary disease; IP, immunophenotype; GVHD, graft-versus-host disease; CNS, central nervous system; Rel, relapse; IT, 
intrathecal chemotherapy; BM, bone marrow; NE, not evaluable; Ref, refractory; RT, radiotherapy; CR, complete remission.
aPelvic mass disappeared after radiotherapy and dasatinib treatment. 
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malignancies who only receive chemotherapy-based 
conditioning for allogeneic transplantation [28]. In the 
international collaborative trial conducted by Goldstone 
et al. [29] (MRC UKALL XII/ECOG E2993), the 5-year 
OS rate for adult ALL patients was 53% for standard-
risk patients and 41% for high-risk patients, while the 
5-year relapse rate was 24% for standard-risk patients 
and 37% for high-risk patients, leading to speculation 
that allogeneic transplantation has the most potent anti-
leukemic effect in adult ALL, as demonstrated by the 
significantly reduced relapse rate (37% with a donor vs. 
63% without a donor, p < 0.001).
In conclusion, our BuFlu regimen would appear to be an 
acceptable conditioning option for lymphoid malignancies, 
including high-risk cases, in terms of OS and EFS. It was 
safely administered with a lower TRM rate compared 
to BuCy2 conditioning. When considering the graft-
versus-leukemia effect, sanctuary site relapse after 
transplantation would not seem to be a significant issue in 
patients with lymphoid malignancies. 
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